KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been
approved to treat these tumors. Despite the recent development of drugs that block KRAS …

The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours
in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive …

Non-rapid eye movement (NREM) sleep, characterized by slow-wave electrophysiological
activity, underlies several critical functions, including learning and memory. However, NREM …

Although it is broadly agreed that the improved treatment of patients with cancer will depend
on a deeper molecular understanding of the underlying pathogenesis, only a few examples …

How can we treat cancer more effectively? Traditionally, tumours from the same anatomical
site are treated as one tumour entity. This concept has been challenged by recent …

A growing number of studies are revealing that cells can send and receive information by
controlling the temporal behavior (dynamics) of their signaling molecules. In this Review, we …

Ten years ago, we wrote a Review on lipid rafts and signalling in the launch issue of Nature
Reviews Molecular Cell Biology. At the time, this field was suffering from ambiguous …

Stem cells are critical to maintaining steady-state organ homeostasis and regenerating
injured tissues. Recent intriguing reports implicate extracellular vesicles (EVs) as carriers for …

Dual‐specificity MAP kinase phosphatases (MKPs) provide a complex negative regulatory
network that acts to shape the duration, magnitude and spatiotemporal profile of MAP kinase …

K-Ras is targeted to the plasma membrane by a C-terminal membrane anchor that
comprises a farnesyl-cysteine-methyl-ester and a polybasic domain. We used quantitative …